Latrepirdine Dihydrochloride, also known as Dimebon, was investigated as a treatment for neurodegenerative diseases like Alzheimer’s and Huntington’s disease, with potential mechanisms including autophagy enhancement and mitochondrial stabilization. However, due to negative results in clinical trials, latrepirdine remains unlicensed and not approved for use in treating these or any other neurodegenerative conditions. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Dimebolin dihydrochloride and Dimebon HCl. Its PubChem CID is 23729232.
Latrepirdine dihydrochloride
| CAS No | 97657-92-6 |
|---|---|
| Molecular Formula | C21H27Cl2N3 |
| Molecular Weight | 392.40 g/mol |
| Synonyms | 2,8-dimethyl-5-[2-(6-methyl-3-pyridinyl)ethyl]-3,4-dihydro-1H-pyrido[4,3-b]indole;dihydrochloride |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Latrepirdine Dihydrochloride, also known as Dimebon, was investigated as a treatment for neurodegenerative diseases like Alzheimer's and Huntington's disease, with potential mechanisms including autophagy enhancement and mitochondrial stabilization.
The listed CAS number is 97657-92-6.
The listed molecular formula is C21H27Cl2N3.
The listed molecular weight is 392.40 g/mol.
2,8-dimethyl-5-[2-(6-methyl-3-pyridinyl)ethyl]-3,4-dihydro-1H-pyrido[4,3-b]indole;dihydrochloride.
The source lists Dimebolin dihydrochloride and Dimebon HCl.